Immediate treatment for recent hepatitis C infection in people with high-risk behaviors: a systematic review and meta-analysis.
Journal
Hepatology communications
ISSN: 2471-254X
Titre abrégé: Hepatol Commun
Pays: United States
ID NLM: 101695860
Informations de publication
Date de publication:
01 04 2023
01 04 2023
Historique:
received:
02
05
2022
accepted:
27
12
2022
entrez:
17
3
2023
pubmed:
18
3
2023
medline:
22
3
2023
Statut:
epublish
Résumé
Direct-acting antivirals (DAAs) are almost exclusively approved for the treatment of chronic HCV. This poses a significant barrier to the treatment of recently acquired HCV because of the limited access to DAAs. This review seeks to address this issue by synthesizing evidence of the benefits and harms of immediate treatment after the detection of recently acquired HCV in people at higher risk of infection. A systematic review and meta-analysis were conducted reporting on populations with recently acquired HCV at higher risk of infection. Studies were included if they assessed standard duration DAA treatment regimens and reported on the benefits and harms of immediate treatment (within one year of diagnosis). Outcomes included sustained virological response at 12 weeks post-treatment (SVR12), incidence, treatment initiation and adherence, overtreatment, engagement in care, and adverse events. Eight cohort studies, 3 open-label trials, and 1 case series study were included, reporting on 2085 participants with recently acquired HCV infection. No studies included a comparison group. Eight studies assessed DAA treatment in either men who have sex with men or men who have sex with men with HIV, 2 studies assessed treatment in people who inject drugs, and 2 among people living with HIV. Immediate treatment of HCV was associated with a pooled SVR12 of 95.9% (95% CI, 92.6%-99.3%). Three studies reported on hepatitis C incidence, where most participants were treated in the chronic phase of infection. A treatment completion rate of 100% was reported in 2 studies, and only 1 serious adverse event was described. High rates of cure were achieved with the treatment of recently acquired hepatitis C in people at higher risk of infection. Serious adverse events were rare, highlighting individual benefits consistent with the treatment of chronic hepatitis C. The impact of immediate treatment on HCV incidence requires further evaluation.
Sections du résumé
BACKGROUND AND AIMS
Direct-acting antivirals (DAAs) are almost exclusively approved for the treatment of chronic HCV. This poses a significant barrier to the treatment of recently acquired HCV because of the limited access to DAAs. This review seeks to address this issue by synthesizing evidence of the benefits and harms of immediate treatment after the detection of recently acquired HCV in people at higher risk of infection.
APPROACH AND RESULTS
A systematic review and meta-analysis were conducted reporting on populations with recently acquired HCV at higher risk of infection. Studies were included if they assessed standard duration DAA treatment regimens and reported on the benefits and harms of immediate treatment (within one year of diagnosis). Outcomes included sustained virological response at 12 weeks post-treatment (SVR12), incidence, treatment initiation and adherence, overtreatment, engagement in care, and adverse events. Eight cohort studies, 3 open-label trials, and 1 case series study were included, reporting on 2085 participants with recently acquired HCV infection. No studies included a comparison group. Eight studies assessed DAA treatment in either men who have sex with men or men who have sex with men with HIV, 2 studies assessed treatment in people who inject drugs, and 2 among people living with HIV. Immediate treatment of HCV was associated with a pooled SVR12 of 95.9% (95% CI, 92.6%-99.3%). Three studies reported on hepatitis C incidence, where most participants were treated in the chronic phase of infection. A treatment completion rate of 100% was reported in 2 studies, and only 1 serious adverse event was described.
CONCLUSIONS
High rates of cure were achieved with the treatment of recently acquired hepatitis C in people at higher risk of infection. Serious adverse events were rare, highlighting individual benefits consistent with the treatment of chronic hepatitis C. The impact of immediate treatment on HCV incidence requires further evaluation.
Identifiants
pubmed: 36930865
doi: 10.1097/HC9.0000000000000082
pii: 02009842-202304010-00002
pmc: PMC10027039
pii:
doi:
Substances chimiques
Antiviral Agents
0
Types de publication
Meta-Analysis
Systematic Review
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : World Health Organization
ID : 001
Pays : International
Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Association for the Study of Liver Diseases.
Références
World Health Organisation. Global Health Sector Strategy on Viral Hepatitis 2016-2021 Towards Ending Viral Hepatitis. World Health Organization; 2016. 2016.
Grebely J, Page K, Sacks-Davis R, van der Loeff MS, Rice TM, Bruneau J, et al. The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection. Hepatology. 2014;59:109–20.
Jin F, Dore GJ, Matthews G, Luhmann N, Macdonald V, Bajis S, et al. Prevalence and incidence of hepatitis C virus infection in men who have sex with men: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2021;6:39–56.
Trickey A, Fraser H, Lim AG, Peacock A, Colledge S, Walker JG, et al. The contribution of injection drug use to hepatitis C virus transmission globally, regionally, and at country level: a modelling study. Lancet Gastroenterol Hepatol. 2019;4:435–44.
Ghany MG, Morgan TR. AASLD-IDSA Hepatitis C Guidance Panel. Hepatitis C Guidance 2019 update: American Association for the Study of Liver Diseases–Infectious Diseases Society of America Recommendations for Testing. Hepatology. 2020;71:686–721.
Pawlotsky J-M, Negro F, Aghemo A, Berenguer M, Dalgard O, Dusheiko G, et al. EASL recommendations on treatment of hepatitis C: final update of the series. J Hepatol. 2020;73:1170–218.
International Network of People Who Use Drugs I. Key Populations’ Values and Preferences for HIV, Hepatitis and STI Services: A Qualitative Study. INPUD; 2021.
Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535.
World Health Organisation. Accelerating access to hepatitis C diagnostics and treatment: overcoming barriers in low- and middle-income countries. Global progress report 2020. Geneva. 2021.
Panel TEATNAHCIC.. Acute hepatitis C in HIV-infected individuals: recommendations from the European AIDS Treatment Network (NEAT) consensus conference. AIDS. 2011;25:399–409.
Munn Z, Barker T, Moola S, Tufanaru C, Stern C, McArthur A, et al. Methodological quality of case series studies. JBI Evid Synth. 2020;18:2127–2133.
Schünemann HJ, Mustafa RA, Brozek J, Steingart KR, Leeflang M, Murad MH, et al. GRADE guidelines: 21 part 2. Test accuracy: inconsistency, imprecision, publication bias, and other domains for rating the certainty of evidence and presenting it in evidence profiles and summary of findings tables. J Clin Epidemiol. 2020;122:142–52.
Schünemann HJ, Mustafa RA, Brozek J, Steingart KR, Leeflang M, Murad MH, et al. GRADE guidelines: 21 part 1. Study design, risk of bias, and indirectness in rating the certainty across a body of evidence for test accuracy. J Clin Epidemiol. 2020;122:129–41.
Boesecke C, Nelson M, Ingiliz P, Lutz T, Scholten S, Cordes C, et al. Can’t buy me love? obstacles to microelimination of acute HCV coinfection in Europe. 26th Conference on Retroviruses and Opportunistic Infections. 2019.
Cannon L, Dhillon R, A T, Teo S, Garner A, Ward C, et al. Hepatitis C infection and treatment outcomes in the DAA era. HIV Med. 2020;21:51.
Chromy D, Mandorfer M, Bucsics T, Schwabl P, Scheiner B, Schmidbauer C, et al. High efficacy of interferon-free therapy for acute hepatitis C in HIV-positive patients. United European Gastroenterol J. 2019;7:507–16.
Cotte L, Hocqueloux L, Lefebvre M, Pradat P, Bani-Sadr F, Huleux T, et al. Microelimination or Not? The Changing Epidemiology of Human Immunodeficiency Virus-Hepatitis C Virus Coinfection in France 2012–2018. Clin Infect Dis. 2021;73:e3266–74.
Garvey LJ, Cooke GS, Smith C, Stingone C, Ghosh I, Dakshina S, et al. Decline in hepatitis C virus (HCV) incidence in men who have sex with men living with human immunodeficiency virus: progress to HCV microelimination in the United Kingdom? Clin Infect Dis. 2020;72:233–8.
Girometti N, Devitt E, Phillips J, Nelson M, Whitlock G. High rates of unprotected anal sex and use of generic direct-acting antivirals in a cohort of MSM with acute HCV infection. J Viral Hepat. 2019;26:627–34.
Huang M-H, Chang S-Y, Liu C-H, Cheng A, Su L-H, Liu W-C, et al. HCV reinfections after viral clearance among HIV-positive patients with recent HCV infection in Taiwan. Liver Int. 2019;39:1860–7.
Gómez-Ayerbe C, Palacios R, Ríos MJ, Téllez F, Sayago C, Martín-Aspas A, et al. Acute hepatitis C virus infection and direct-acting antiviral drugs: perfect combination to eliminate the epidemic? Int J STD AIDS, 32:1257–60. doi:10.1177/09564624211033756.
doi: 10.1177/09564624211033756
Matthews GV, Bhagani S, Van der Valk M, Rockstroh J, Feld JJ, Rauch A, et al. Sofosbuvir/velpatasvir for 12 vs. 6 weeks for the treatment of recently acquired hepatitis C infection. J Hepatol. 2021;75:829–39.
Braun DL, Hampel B, Ledergerber B, Grube C, Nguyen H, Künzler-Heule P, et al. A treatment-as-prevention trial to eliminate hepatitis C among men who have sex with men living with human immunodeficiency virus (HIV) in the Swiss HIV cohort study. Clin Infect Dis. 2020. doi: 10.1093/cid/ciaa1124
doi: 10.1093/cid/ciaa1124
Naggie S, Fierer DS, Hughes MD, Kim AY, Luetkemeyer A, Vu V, et al. Ledipasvir/sofosbuvir for 8 weeks to treat acute hepatitis C virus infections in men with human immunodeficiency virus infections: sofosbuvir-containing regimens without interferon for treatment of acute HCV in HIV-1 infected individuals. Clin Infect Dis. 2019;69:514–22.
Palaniswami PM, El Sayed A, Asriel B, Carollo JR, Fierer DS. New York acute hepatitis CSN. Ledipasvir and sofosbuvir in the treatment of early hepatitis C virus infection in HIV-infected men. Open Forum Infect Dis. 2018;5:ofy238 ofy238.
Latham NH, Doyle JS, Palmer AY, Vanhommerig JW, Agius P, Goutzamanis S, et al. Staying hepatitis C negative: a systematic review and meta-analysis of cure and reinfection in people who inject drugs. Liver Int. 2019;39:2244–60.
Doyle JS, van Santen DK, Iser D, Sasadeusz J, O’Reilly M, Harney B, et al. Microelimination of hepatitis C among people with human immunodeficiency virus coinfection: declining incidence and prevalence accompanying a multicenter treatment scale-up trial. Clin Infect Dis. 2020;73:e2164–72.
Popping S, Hullegie SJ, Boerekamps A, Rijnders BJA, de Knegt RJ, Rockstroh JK, et al. Early treatment of acute hepatitis C infection is cost-effective in HIV-infected men-who-have-sex-with-men. PLoS One. 2019;14:e0210179.
Liu Y, Zhang H, Zhang L, Zou X, Ling L. Economic evaluation of hepatitis C treatment extension to acute infection and early-stage fibrosis among patients who inject drugs in developing countries: a case of China. Int J Environ Res Public Health. 2020;17:800.
Bethea ED, Chen Q, Hur C, Chung RT, Chhatwal J. Should we treat acute hepatitis C? A decision and cost-effectiveness analysis. Hepatology. 2018;67:837–46.
Mukherjee S, Colby D, Ramautarsing R, Popping S, Sriplienchan S, Chinbunchorn T, et al. Expanding reimbursement of immediate treatment using direct acting antivirals to reduce hepatitis C incidence among HIV positive men who have sex with men in Bangkok, Thailand: a cost effectiveness modelling study. J Virus Erad. 2021;7:100042.
Martinello M, Hellard M, Shaw D, Petoumenos K, Applegate T, Grebely J, et al. Short duration response-guided treatment is effective for most individuals with recent hepatitis C infection: the ATAHC II and DARE-C I studies. Antivir Ther. 2015;21:425–34.
Santantonio T, Fasano M, Sagnelli E, Tundo P, Babudieri S, Fabris P, et al. Acute hepatitis C: a 24‐week course of pegylated interferon alpha‐2b versus a 12‐week course of pegylated interferon alpha‐2b alone or with ribavirin. Hepatology. 2014;59:2101–9.
Calleri G, Cariti G, Gaiottino F, De Rosa FG, Bargiacchi O, Audagnotto S, et al. A short course of pegylated interferon‐α in acute HCV hepatitis. J Viral Hepat. 2007;14:116–21.
Martinello M, Orkin C, Cooke G, Bhagani S, Gane E, Kulasegaram R, et al. Short-duration pan-genotypic therapy with glecaprevir/pibrentasvir for 6 weeks among people with recent hepatitis C viral infection. Hepatology. 2020;72:7–18.
Rockstroh JK, Bhagani S, Hyland RH, Yun C, Dvory-Sobol H, Zheng W, et al. Ledipasvir–sofosbuvir for 6 weeks to treat acute hepatitis C virus genotype 1 or 4 infection in patients with HIV coinfection: an open-label, single-arm trial. Lancet Gastroenterol Hepatol. 2017;2:347–53.
Boerekamps A, De Weggheleire A, van den Berk GE, Lauw FN, Claassen MAA, Posthouwer D, et al. Treatment of acute hepatitis C genotypes 1 and 4 with 8 weeks of grazoprevir plus elbasvir (DAHHS2): an open-label, multicentre, single-arm, phase 3b trial. Lancet Gastroenterol Hepatol. 2019;4:269–77.
Micallef JM, Kaldor JM, Dore GJ. Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. J Viral Hepat. 2006;13:34–41.
Grebely J, Raffa JD, Lai C, Krajden M, Conway B, Tyndall MW. Factors associated with spontaneous clearance of hepatitis C virus among illicit drug users. Can J Gastroenterol. 2007;21:796325.